Impact of objective response and overall survival in patients with inoperable or metastatic gastric and esophagogastric junction (EGJ) cancer: Landmark analysis of 10 year data from first-line clinical trials

被引：0
|
作者：
Bolt, T. A. [1 ]
Pauligk, C. [1 ]
Werner, D. [1 ]
Mayer, F. [2 ]
Hofheinz, R. [3 ]
Nils, H. [4 ]
Luley, K. [5 ]
Schmalenberg, H. [6 ]
Egger, M. [7 ]
Al-Batran, S-E. [1 ]
机构：
[1] Krankenhaus Norwest, Inst Klin Onkol Forsch, Frankfurt, Germany
[2] Univ Med Ctr, Tubingen, Germany
[3] Univ Med Ctr, Dept Hematol & Med Oncol, Mannheim, Germany
[4] Klinikum Wolfsburg, Wolfsburg, Germany
[5] Univ Klinikum Lubeck, Lubeck, Germany
[6] Univ Tumorctr Jena, Jena, Germany
[7] Ortenau Klinikum, Lahr Ettenheim, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：52 / 52
页数：1
相关论文
共 50 条
  • [31] The impact of young age on survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program
    Lieu, C.
    Renfro, L.
    De Gramont, A.
    Maughan, T. S.
    Seymour, M. T.
    Saltz, L.
    Goldberg, R. M.
    Sargent, D.
    Eckhardt, S. G.
    Eng, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S483 - S483
  • [32] Effect of subsequent chemotherapy on overall survival in first-line chemotherapy with targeted agents for patients with metastatic colorectal cancer: Systematic review and meta-analysis of randomized control trials.
    Sakai, Daisuke
    Kudo, Toshihiro
    Kato, Aya
    Sueda, Toshinori
    Takahashi, Hidekazu
    Haraguchi, Naotsugu
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    Satoh, Taroh
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [33] Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival
    Gradishar, William J.
    Krasnojon, Dimitry
    Cheporov, Sergey
    Makhson, Anatoly N.
    Manikhas, Georgiy M.
    Clawson, Alicia
    Bhar, Paul
    McGuire, John R.
    Iglesias, Jose
    CLINICAL BREAST CANCER, 2012, 12 (05) : 313 - 321
  • [34] Overall survival with non-proportional hazards in first-line treatment for patients with metastatic colorectal cancer: Systematic review and network meta-analysis
    Keshavarzi, Fatemeh
    Salari, Nader
    Jambarsang, Sara
    Tabatabaei, Seyyed Mohammad
    Shahsavari, Soodeh
    Fournier, Andrew J.
    HELIYON, 2024, 10 (16)
  • [35] EFFICACY AND SAFETY OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER (MCRC): FIRST-LINE ANALYSIS OF POOLED DATA FROM RANDOMIZED CONTROLLED TRIALS (RCTS)
    Kabbinavar, F. F.
    Hurwitz, H. I.
    Tebbutt, N. C.
    Giantonio, B. J.
    Guan, Z.
    Mitchell, L.
    Waterkamp, D.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 189 - 189
  • [36] No impact of first-line systemic therapy on quality of life of patients with metastatic breast cancer? Data from the MaLife-project
    Marschner, N.
    Tesch, H.
    Karcher, A.
    Ammon, A.
    Nusch, A.
    Boller, E.
    Spring, L.
    Jaenicke, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 111 - 111
  • [37] Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival
    Berruti, A
    Zola, P
    Buniva, T
    Bau, MG
    Farris, A
    Sarobba, MG
    Bottini, A
    Tampellini, M
    Durando, A
    Destefanis, M
    Monzeglio, C
    Moro, G
    Sussio, M
    Perroni, D
    Dogliotti, L
    ANTICANCER RESEARCH, 1997, 17 (4A) : 2763 - 2768
  • [38] Overall survival of men with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line docetaxel-containing chemotherapy according to their participation (or not) in clinical trials.
    Goyal, Jatinder
    Huang, Peng
    Tyagi, Prachi
    Oh, Daniel
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [39] Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: An updated meta-analysis of ten randomized controlled trials
    Qi, Wei-Xiang
    Shen, Zan
    Lin, Feng
    Sun, Yuan-Jue
    Min, Da-Liu
    Tang, Li-Na
    He, Ai-Na
    Yao, Yang
    INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (02) : E66 - E73
  • [40] Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy
    Kasahara, Norimitsu
    Imai, Hisao
    Kaira, Kyoichi
    Mori, Keita
    Wakuda, Kazushige
    Ono, Akira
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Harada, Hideyuki
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Nakajima, Takashi
    Yamada, Masanobu
    Takahashi, Toshiaki
    RADIOLOGY AND ONCOLOGY, 2015, 49 (04) : 409 - 415
12345